±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 412  |  »Ø¸´: 1

yaoguiyang

ľ³æ (СÓÐÃûÆø)

[ÇóÖú] ÇóÖú¹¹Ð§¹ØÏµµÄ·­Òë

Traditionally, the immunosuppressive potential of cyclosporin
derivatives was tested in isolated T-cell assays. In this
context, the immunosuppressive activity of cyclosporins largely
correlates with the ability of cyclophilin A−cyclosporin
complexes to inhibit the activity of calcineurin. However, as
described above, cyclophilins appear to be involved in other
immune response processes such as innate immunity and
inflammation. In order to explore the potential of cyclophilin
inhibitors to act as inhibitors of leukocyte trafficking by
inhibiting extracellular cyclophilins, a series of impermeable
cyclosporins were prepared.83 The benzimidazole derivative 15
(Figure 9) was determined to have a similar affinity to
cyclophilin A as 1 in an in vitro proline isomerase binding assay.
A cellular cyclophilin binding assay developed using a
fluorescently labeled cyclophilin derivative revealed that 15 is
at least 50-fold less permeable than 1. As expected, despite its
significant restriction to the extracellular space, 15 inhibits
leukocyte migration toward cyclophilin A. This inhibitor also
reduces leukocyte activation in a mouse model of allergic
contact hypersensitivity.
Although detailed data are not available, in a patent filing
Scynexis explored the potential for alkylation at P5 to influence
the immunosuppressive activity and antiviral potency of 1.119
Earlier, chemists at Sandoz had demonstrated that alkylation of
the free NH at this position can influence the conformation and
immunsuppressive activity of cyclosporin derivatives.120 Compound
16 (Figure 10) was prepared via alkylation of [(D)-
MeAla]3-CsA with dimethylallyl bromide. This analogue was
reported to bind to cyclophilins A and D with good (<60 nM)
potency and to have an EC50 in the replicon assay of less than
200 nM. Furthermore, in a standard stimulated T-cell assay, 12
was found to be at least a 40-fold less potent inhibitor of IL-2
release than 1.

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

yaoguiyang

ľ³æ (СÓÐÃûÆø)

2Â¥2014-11-30 11:06:32
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ yaoguiyang µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0854Çóµ÷¼Á +4 assdll 2026-04-04 4/200 2026-04-05 09:44 by zhq0425
[¿¼ÑÐ] 304Çóµ÷¼Á£¨085602£¬¹ýËļ¶£¬Ò»Ö¾Ô¸985£© +12 »¯¹¤ÈË999 2026-04-04 12/600 2026-04-05 09:15 by sam3303
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +7 dxyµ÷¼Á 2026-04-04 7/350 2026-04-05 09:15 by İÇï26
[¿¼ÑÐ] 0832ʳƷ¿ÆÑ§Ó빤³Ìѧ˶282µ÷¼Á +5 ÓãÔÚË®ÖÐÓÎa 2026-04-02 8/400 2026-04-05 09:06 by llyytt
[¿¼ÑÐ] 11408,335·Ö£¬±¾¿Æ211£¬Çóµ÷¼Á£¬¿Éתרҵ +5 öùÀæ´óöùÓã 2026-04-03 5/250 2026-04-04 22:49 by chongya
[¿¼ÑÐ] 086000ÉúÎïÓëÒ½Ò©298µ÷¼ÁÇóÖú +6 ÔªÔªÇàÇà 2026-03-31 8/400 2026-04-04 22:15 by lys0704
[¿¼ÑÐ] 358Çóµ÷¼Á +5 Çïgk 2026-04-04 5/250 2026-04-04 21:03 by dongzh2009
[¿¼ÑÐ] 349Çóµ÷¼Á +11 zwjjjjjj 2026-03-31 11/550 2026-04-04 19:52 by À¶ÔÆË¼Óê
[¿¼ÑÐ] Çóµ÷¼Á +3 ũҵ¹¤³ÌÓëÐÅÏ¢¼ 2026-04-04 3/150 2026-04-04 12:19 by Éá¶øºóµÃ
[¿¼ÑÐ] 320µ÷¼Á +4 ũҵ¹¤³ÌÓëÐÅÏ¢¼ 2026-04-03 4/200 2026-04-03 21:40 by lbsjt
[¿¼ÑÐ] ¹¤¿Æ341·Öµ÷¼Á +3 Âå¶àÂÞ 2026-04-03 3/150 2026-04-03 14:20 by 1753564080
[¿¼ÑÐ] 0703»¯Ñ§ +7 goldtt 2026-04-02 9/450 2026-04-03 09:36 by À¶ÔÆË¼Óê
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©¿Æ¼¼´óѧ²ÄÁÏѧ˶328·ÖÇóµ÷¼Á +6 1¶Îʱ¼ä 2026-03-31 7/350 2026-04-02 13:57 by 3041
[¿¼ÑÐ] 337Çóµ÷¼Á +11 ¡¶Ê÷¡· 2026-03-29 11/550 2026-04-02 10:20 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] 285Çóµ÷¼Á +11 AZMK 2026-04-01 11/550 2026-04-01 22:40 by peike
[¿¼ÑÐ] 085602»¯Ñ§¹¤³Ì268·Ö¶×µ÷¼Á +8 ÔÂÕÕ»¨ÁÖ¡£ 2026-04-01 8/400 2026-04-01 22:08 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 298Çóµ÷¼Á +4 ʲôÊÇÅÖÍ·Óã 2026-03-30 6/300 2026-04-01 22:06 by ¿Í¶ûÃÀµÂ
[¿¼ÑÐ] 292Çóµ÷¼Á +17 ľ³æer12138 2026-04-01 17/850 2026-04-01 21:37 by Æß¶È²»ÐÅÈÎ
[¿¼ÑÐ] »·¾³¹¤³Ìµ÷¼Á +9 hyzzzzzzz. 2026-04-01 9/450 2026-04-01 14:20 by salamander`
[Óлú½»Á÷] ¼×»ùÑǻǻÇËáÄÆºÍ¼×»ù»ÇËáõ¥·´Ó¦»úÀí 10+3 kaobao456 2026-03-29 4/200 2026-03-30 23:16 by nBuï®
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û